Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome

R. K. Silver*, A. M. Peaceman, D. M. Adams

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

As clinicians include an immunologic evaluation in their assessment of recurrent fetal loss among otherwise asymptomatic women, the diagnosis of PAPS will be uncovered with greater frequency. Our understanding of the underlying pathophysiology of PAPS is critical if we are to propose safe and rational therapies for these patients. It appears as though prostaglandin metabolites are implicated directly in the processes that culminate in this unique, localized vasculopathy; and research is actively progressing with this focus in mind. For the present, we should look critically at the available treatments to be sure that the rationale for use is consistent with current evidence and that the margin of fetal and maternal safety justifies their use. To date, only low-dose aspirin appears to alter prostaglandin metabolites favorably and is thus, emerging as our safest and most efficacious treatment.

Original languageEnglish (US)
Pages (from-to)357-373
Number of pages17
JournalClinics in Perinatology
Volume22
Issue number2
StatePublished - Jan 1 1995

Fingerprint

Antiphospholipid Syndrome
Platelet Activating Factor
Prostaglandins
Aspirin
Therapeutics
Mothers
Safety
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{784459e455c043bc801ce17323200a14,
title = "Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome",
abstract = "As clinicians include an immunologic evaluation in their assessment of recurrent fetal loss among otherwise asymptomatic women, the diagnosis of PAPS will be uncovered with greater frequency. Our understanding of the underlying pathophysiology of PAPS is critical if we are to propose safe and rational therapies for these patients. It appears as though prostaglandin metabolites are implicated directly in the processes that culminate in this unique, localized vasculopathy; and research is actively progressing with this focus in mind. For the present, we should look critically at the available treatments to be sure that the rationale for use is consistent with current evidence and that the margin of fetal and maternal safety justifies their use. To date, only low-dose aspirin appears to alter prostaglandin metabolites favorably and is thus, emerging as our safest and most efficacious treatment.",
author = "Silver, {R. K.} and Peaceman, {A. M.} and Adams, {D. M.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "357--373",
journal = "Clinics in Perinatology",
issn = "0095-5108",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome. / Silver, R. K.; Peaceman, A. M.; Adams, D. M.

In: Clinics in Perinatology, Vol. 22, No. 2, 01.01.1995, p. 357-373.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome

AU - Silver, R. K.

AU - Peaceman, A. M.

AU - Adams, D. M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - As clinicians include an immunologic evaluation in their assessment of recurrent fetal loss among otherwise asymptomatic women, the diagnosis of PAPS will be uncovered with greater frequency. Our understanding of the underlying pathophysiology of PAPS is critical if we are to propose safe and rational therapies for these patients. It appears as though prostaglandin metabolites are implicated directly in the processes that culminate in this unique, localized vasculopathy; and research is actively progressing with this focus in mind. For the present, we should look critically at the available treatments to be sure that the rationale for use is consistent with current evidence and that the margin of fetal and maternal safety justifies their use. To date, only low-dose aspirin appears to alter prostaglandin metabolites favorably and is thus, emerging as our safest and most efficacious treatment.

AB - As clinicians include an immunologic evaluation in their assessment of recurrent fetal loss among otherwise asymptomatic women, the diagnosis of PAPS will be uncovered with greater frequency. Our understanding of the underlying pathophysiology of PAPS is critical if we are to propose safe and rational therapies for these patients. It appears as though prostaglandin metabolites are implicated directly in the processes that culminate in this unique, localized vasculopathy; and research is actively progressing with this focus in mind. For the present, we should look critically at the available treatments to be sure that the rationale for use is consistent with current evidence and that the margin of fetal and maternal safety justifies their use. To date, only low-dose aspirin appears to alter prostaglandin metabolites favorably and is thus, emerging as our safest and most efficacious treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029006663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029006663&partnerID=8YFLogxK

M3 - Review article

VL - 22

SP - 357

EP - 373

JO - Clinics in Perinatology

JF - Clinics in Perinatology

SN - 0095-5108

IS - 2

ER -